ArticleJournal of endocrinological investigation2025
Prognostic markers in pheochromocytomas/paragangliomas: the role of histopathology, SDHB, MAML3 and MCM6 expression.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone metastases in pheochromocytomas and paragangliomas: a narrative review of presentation, diagnosis and management.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere are currently no definitive prognostic markers that accurately predict malignant behavior in pheochromocytoma/paraganglioma (PCC/PGL). While metastasis develops in only 10-15% of adrenal-origin, this rate can rise up to 50% in those with extra-adrenal localization. This study aims to investigate the potential predictive effect of known histopathological features in PCC/PGL, alongside SDHB, S100, Ki-67 proliferation index, and the expression of MAML3 and MCM6 in predicting metastatic disease.
methodsThe specimens of 71 patients who were diagnosed with PCC/PGL and underwent total excision between 2010 and 2021 were re-examined. Demographic, clinical, and histopathological data, as well as immunohistochemical results for Ki-67, S100, SDHB, MCM6, and MAML3, were recorded.
resultsWhile distant organ metastasis was observed in 3.4% (n = 1/29) of PCC and 21.2% (n = 7/33) of head and neck PGL, this rate was found to be significantly higher at 66.7% (n = 6/9) in abdominal PGL (p < 0.001). No MAML3 overexpression was observed in any of the cases. Distant organ metastasis was more frequently detected in cases with MCM6 overexpression.
conclusionsAlthough there is still no definitive feature that predicts metastasis, in line with the literature, extra-adrenal localization, vascular invasion, capsular invasion, nuclear pleomorphism, hyperchromasia, and confluent necrosis were found to be associated with distant organ metastasis in our study. Additionally, in the multivariate analysis, larger tumor size (> 5.1 cm), the presence of > 3/10 HPF mitosis, and SDHB loss were associated with lower metastasis-free survival. While no conclusions could be drawn regarding MAML3, the prognostic value of MCM6 appears promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.